| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||
|
AK_Francis
Supreme |
28-Aug-2008 16:26
Yells: "Happy go lucky, cheers." |
||
|
x 0
x 0 Alert Admin |
vol not high. BBs chow yesdy liao, I think. | ||
| Useful To Me Not Useful To Me | |||
|
limhpp
Veteran |
28-Aug-2008 16:11
|
||
|
x 0
x 0 Alert Admin |
Ya..This counter up 3 days and down about 2 weeks...and up again..... Keeps repeating ......since beginning of this month... |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
pikachu
Veteran |
28-Aug-2008 15:35
Yells: "Holy Cow!" |
||
|
x 0
x 0 Alert Admin |
This counter very crazy. Up and down very fast. Chances of getting burn is very high. |
||
| Useful To Me Not Useful To Me | |||
|
AK_Francis
Supreme |
28-Aug-2008 12:14
Yells: "Happy go lucky, cheers." |
||
|
x 0
x 0 Alert Admin |
Jack!!!now early the morning leh. nontheless, lets ORCHESTRA this burger together. cheers. |
||
| Useful To Me Not Useful To Me | |||
|
jackjames
Elite |
28-Aug-2008 12:02
|
||
|
x 0
x 0 Alert Admin |
slow and steady is better.. sometimes, so fast reaching orgasm is bad... it can drop dead fast, LOL.. | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
bengster68
Master |
28-Aug-2008 09:56
|
||
|
x 0
x 0 Alert Admin |
Let the contra players get out first. Moving up slowly and steady. One week later sure higher price than now. Many retail punters don't even know what is LEADERS or ESC2008. Some don't even know what is DES. Some investors scared the LEADERS results jialat and sell now. I think Biomatrix sure can slam dunk Cypher. Hope after positive LEADERS results got institutional funds specialising in Biomed start to buy BIG shares. | ||
| Useful To Me Not Useful To Me | |||
|
AK_Francis
Supreme |
28-Aug-2008 09:44
Yells: "Happy go lucky, cheers." |
||
|
x 0
x 0 Alert Admin |
no support after opened. look like it fading away. AK view. | ||
| Useful To Me Not Useful To Me | |||
|
novena_33
Veteran |
28-Aug-2008 09:12
|
||
|
x 0
x 0 Alert Admin |
at what price it hit or close ..... i guess, if u r a contra player...i sure u will be out...... if the results is NUMBER 1...... i'm sure this price to let go is permature...... im quite sure ppl will not let the whole world know...when they r doing badly right...... |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
jasonrxz
Senior |
28-Aug-2008 08:58
|
||
|
x 0
x 0 Alert Admin |
saw the smooth and fast recovery road of big.... today will see it soar to 66cts for sure if not i will run off from it.... cheers and let's have action in mins prior opening... Huat ar.... BIG cheong ar!!!!!!!!!!!!!! 
|
||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 18:32
|
||
|
x 0
x 0 Alert Admin |
Nice close at 60.5cts! Looks like there is strong accumulation from institutional buying. Marching up slowly but surely. I will tell you why LEADERS results is the most important thing that will ever happen to Biosensors. Any DES can get CE Mark. Even Taxus DES and Conor's Costar DES can get CE Mark. But absolutely no other DES players can come close to what Biosensors can achieve clinically. Even if JNJ give their in-house R&D scientists a 5 years period and set aside US$1,000,000,000/= cash to burn for DES R&D program, i seriously think they also cannot come out with something better than Biosensors. If they can and have the time to waste on R&D, why would JNJ want to pay US$1,400,000,000/= cash to buy over Conor? BIG is not only top class in clinical results, BIG also managed to squeeze out the most value out of the money being invested in R&D program. LEADERS will be Biosensor's biggest break and be recognised best stent developer in the world. Sales will increase exponentially, M&A offers should follow soon. MNCs don't buy over your company just because you have CE Mark. These MNCs already has all the skills and connections to get CE Mark at double quick time. What MNCs want are best of the best clinical data. Its really very very difficult to get the best of the best clinical data. For biomed / pharma / medical device industry whereby its always MNCs vs MNCs, the MNC with the best clinical data will definitely be the market leader. Even if any one of these MNCs are prepared to spend the billions in R&D, there is very little guarantee that they will eventually achieve what they hope for clinically. Many R&D programs flopped eventually. Abbott's Zomaxx DES R&D program was one fine example. After spending a few years and burning hundreds of millions cash on Zomaxx R&D program, Abbott gave up and chose to spend US$4,100,000,000/= cash to buy up Xience R&D program. M&A is the most certain and surest way to get something that the MNC like. DES industry is almost US$6,000,000,000/= at stake per year business. Hugely lucrative if the MNC's clinical data is the best and the MNC can sell it on a very massive scale and dominate the industry. Clinical data is all that matters for these top MNCs. Once they have it, the rest is just operational and they will have the means to automatically dominate the industry. |
||
| Useful To Me Not Useful To Me | |||
|
AK_Francis
Supreme |
27-Aug-2008 18:04
Yells: "Happy go lucky, cheers." |
||
|
x 0
x 0 Alert Admin |
don't hope much, reduce paper loss hoe shei liao. cheers for all the supporters. | ||
| Useful To Me Not Useful To Me | |||
|
jackjames
Elite |
27-Aug-2008 17:01
|
||
|
x 0
x 0 Alert Admin |
heee.. september 1st is the big date to see how good is the result they present.. so, we still have couple more days to bull run, heee hee heee... at least, i would say, at least, this counter is not like other counter, dropping shit.. and not recover yet... that is true. |
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
bengster68
Master |
27-Aug-2008 16:29
|
||
|
x 0
x 2 Alert Admin |
Bro A02041315!!! We were all waiting for you!!! BIOSENSORS!!!!!!!!!!!!!!!! CHEEEEEEONG!!!!!!!!!!!! ARRRGGGGGHHH!!!!!!!! Break 65cts today!!! CHEEEEEEEEEEONGGG!!! |
||
| Useful To Me Not Useful To Me | |||
|
A02041315
Senior |
27-Aug-2008 16:26
|
||
|
x 0
x 0 Alert Admin |
Beng Gor, A0204 Lai Loh!!!!!! BIG !!!!!!!!!!CHEONG!!!!!!!!AR!!!!!!!!!!!!!!!! DUN STOP CHEONG!!!!!!!!!!!!!!!!JI PA BAN DEPEND ON YOU! YOU! YOU! CHEER!!!!!!!!!!!!
|
||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 15:20
|
||
|
x 0
x 0 Alert Admin |
Boh gau chiong lat leh........ Lai Lah Lai Lah!!!! BIOSENSORS CHEEEONG ARRGHHHHH!!! 
Where is the cheerleader Mark Gor and A0124590??? |
||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 14:48
|
||
|
x 0
x 0 Alert Admin |
Slowly but surely BIG's share price is marching forward!!! 90cts after LEADERS results??? Last year 29/10/2007 after NOBORI trial results BIG chionged from around 70cts to 99cts. Thats 30cts chiong within 3 days. LEADERS is so much more important than NOBORI. | ||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 13:54
|
||
|
x 0
x 0 Alert Admin |
Mark Gor, Mai Kan Chiong. I have a feeling Biomatrix is going to slam dunk JNJ's Cypher. Sure chiong very hiong after LEADERS results. Best Of The Best DES. Lowest TLR, MACE rates and possibly zero late-thrombosis cases again. Biosensors will be the media limelight at ESC2008 and make all the top DES manufacturers using durable polymer technology super Lau Kwee. | ||
| Useful To Me Not Useful To Me | |||
|
XiaoMaGe888
Senior |
27-Aug-2008 13:24
|
||
|
x 0
x 1 Alert Admin |
BRO>BENG<，
HUAT LIAO LA！ ！ ！ ！ ！ ！ ！ ！ ！ ！ ！ ！ ！ ！ ！
JI PA BAN LIAO (SINGAPORE $)！ ！ ！ ！ ！ ！ ！ ！ ！ ！
|
||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 11:39
|
||
|
x 0
x 0 Alert Admin |
Shares of medical technology company Biosensors International (BIOS.SI: Quote, Profile, Research) soared by 9.4 percent on Tuesday after it said it would be presenting the results of a clinical trial of one of its heart stents next month. A trader called the announcement a "catalyst" awaited by investors amid poor stock market sentiment. Biosensors shares were 6.6 percent higher at S$0.565 by 0732 GMT, while the broader market .FTSTI was 1.2 percent lower. Turnover was heavy with nearly 5 million shares traded. "The announcement will make it more visible and might help it move into the guarded American market. Biosensors has struggled in the past but it should have overcome most of its worst challenges. I anticipate sales growth in Asia, China and Europe," said another trader from a local securities firm. Biosensors said it would present the results of the clinical trial at the European Society of Cardiology meeting in Germany on Sept 1. [ID:nSN8Q50271] The company said the nine-month trial is expected to produce results confirming the safety and efficacy of its "BioMatrix" system. |
||
| Useful To Me Not Useful To Me | |||
|
bengster68
Master |
27-Aug-2008 00:43
|
||
|
x 0
x 0 Alert Admin |
Wah like that JNJ's stent engineers are very jialat leh....... Anyway, a piece of good news for you Mr Investor. Im sure it will impress you since you are really a deep admirer of Xtent for long lesion treatment. Xtent is very zhai also. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention Tuesday August 26, 8:00 am ET MENLO PARK, Calif., Aug. 26 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT - News) today announced that the positive one-year follow-up data from the CUSTOM II trial was published in the most recent issue of the peer-reviewed journal, EuroIntervention. The lead author of the article was Dr. Pieter R. Stella, M.D., of University Medical Center Utrecht, Utrecht, The Netherlands on behalf of the CUSTOM II Investigators from 13 clinical sites across Europe. The one-year CUSTOM II trial, a single-arm, 100-patient prospective study designed to evaluate the safety and efficacy of XTENT's Custom NX® drug-eluting stent (DES) system in patients with coronary artery disease, showed no new major adverse cardiac events (MACE) since the first analysis was performed at six months. The incidence of late stent thrombosis for patients treated with Custom NX in the study was zero percent. CUSTOM II one-year follow-up results were first presented last year at Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. "This article marks our second publication of Custom NX data in this prestigious peer-reviewed journal this year," said Gregory D. Casciaro, XTENT's president and CEO. "We have been extremely pleased with the safety and efficacy Custom NX has demonstrated in the CUSTOM I, II and III trials, and appreciate the level of interest and support our technology continues to receive from the clinical community." Results from the two-year follow-up of CUSTOM I, a 30-patient first-in-man study designed to evaluate the preliminary safety and feasibility of in-situ stent customization, were also published in EuroIntervention earlier this year. This study showed no new major adverse cardiac events (MACE) were reported since the one-year analysis, and the incidence of late stent thrombosis for patients treated with Custom NX was zero percent. The CUSTOM I article published in EuroIntervention was recognized by the journal's editorial board as one of the six best papers submitted to the journal during the previous winter, and Lutz Buellesfeld, M.D., of the HELIOS Heart Center in Siegburg, Germany, received an award in conjunction with the publication after presenting it at the annual EuroPCR meeting in May. The CUSTOM II trial was designed to evaluate the safety and efficacy of Custom NX for the treatment of long and multiple lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long-lesion arm, and 31 patients were enrolled in the two-lesion arm of the study. CUSTOM II enrolled one of the most difficult to treat patient populations ever studied in a DES trial. In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Twenty-six percent of the study participants were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. CUSTOM II's six-month clinical results have been sustained at one year. The target lesion revascularization rate remained constant at four percent, with no new MACE events, and no late stent thrombosis. The EuroIntervention paper, titled "One year results of a new in-situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: result of the CUSTOM-II trial," can be accessed at: http://www.europcronline.com/eurointervention/15th_issue/37/. |
||
| Useful To Me Not Useful To Me | |||
SHA!
SHA!
